Compare Goldman Sachs Physical Gold ETF (AAAU) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Goldman Sachs Physical Gold ETF vs GSK plc — how do they compare? Goldman Sachs Physical Gold ETF trades at $40.03, while GSK plc trades at $52.82 (market cap $105.91B). The key difference: GSK plc pays a 3.38% dividend while Goldman Sachs Physical Gold ETF pays none, and GSK plc is trading nearer its 52-week high, Goldman Sachs Physical Gold ETF nearer its low. Which is the better fit depends on your goals.
| AAAU | GSK | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $53.21 | $61.18 |
52-Week Low | $32.29 | $36.20 |
Market Cap | — | $105.91B |
Enterprise Value | — | $126.53B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAAU, a US-listed gold-focused investment vehicle, trades at $41.04 with a 1.01% daily gain. Technical indicators show a bearish bias with moving averages signaling selling pressure, while oscillators remain neutral. The stock faces resistance at $41 with support at $40. Recent gold market dynamics show central bank accumulation and analyst price targets ranging from $4,500-$5,500 per ounce for the underlying commodity.
Gold's structural tailwinds from central bank demand and inflation hedging support long-term upside, though near-term headwinds include Fed policy uncertainty and dollar strength. The stock offers exposure to gold's safe-haven appeal but remains vulnerable to interest rate volatility and technical resistance levels.
GSK trades at $53.32, down 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $1.24 EPS, and maintains robust profitability with a 17.78% net income margin. Recent FDA approval for Utebzi and the $10.6 billion acquisition of Nuvalent highlight strategic expansion in oncology and anti-infectives.
Outlook remains positive with 7-9% EPS growth guidance for 2026, though risks include integration of large acquisitions and patent cliffs. Analyst consensus is mixed with 31% buy ratings, but solid fundamentals and recent approvals support a constructive view for long-term investors amid sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Goldman Sachs Physical Gold ETF
AAAU tracks the price of gold bullion by holding physical gold bars in secure vaults. Managed by Goldman Sachs, this ETF offers a cost-effective way to gain direct exposure to gold without the logistical challenges of storage or insurance.
Read more on AAAU →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
